In the beginning when insulinoma mass is small, use of glucagon may have some benefit but creating a futile cycle is not a long-term solution.
About half of the insulinoma do have somatostatin receptors (subtype 2) and respond to its analogue, which helps with reducing hypoglycemia. Ultimately, as the insulinoma mass increases, the only practical solution is to eliminate it - which is currently done surgically.